Exposure to Potentially Dangerous Drug-Drug Interactions Involving Antipsychotics
Abstract
Objective
Antipsychotic drug therapy is the cornerstone of treatment of persons with schizophrenia. Because most antipsychotics are metabolized by the hepatic cytochrome P450 system, concomitant use of an antipsychotic and medications that are competitively metabolized by the same system may cause a potentially harmful drug-drug interaction. This study used a large state's Medicaid claims database to examine the proportion of patients exposed to such interactions and the risk factors associated with exposure.
Methods
Claims from January 2000 through December 2003 for adult patients with a diagnosis of schizophrenia and at least one prescription for an antipsychotic (N=27,909) were examined for pairs of medications identified as potentially causing moderate or severe adverse drug effects. Logistic regression models were estimated to determine potential risk factors associated with exposure to the interaction pairs.
Results
A total of 6,417 (23%) patients were exposed to 14,213 potentially harmful interactions; 4,725 patients had at least one exposure from the same pharmacy, and 4,032 patients were exposed by the same physician. The greatest number of exposures (N=1,353) to potentially harmful combinations involved olanzapine and haloperidol. Patients prescribed risperidone were most likely to be exposed to an interaction (13.1%), followed by patients prescribed olanzapine (10.3%), quetiapine (3.3%), and clozapine (3.2%). A higher risk of exposure was associated with being female (odds ratio [OR]=.94), being white (OR=1.43), having depression (OR=1.21), or having impulse-control disorder (OR=1.98).
Conclusions
Interventions by physicians and pharmacies to reduce the prescribing and dispensing of potentially harmful pairs of medications to patients with schizophrenia are recommended.
Drug-related morbidity and mortality are major medical issues with significant costs. Each year an estimated $177.4 billion is spent to address the treatment failures and new medical problems that are generated by adverse drug events (1,2). Such events occur in up to 40% of patients on five or more medications (3–5). It has been estimated that 6% to 10% of adverse events are drug-drug interactions and that 50% to 84% of adverse events are preventable through proper identification and surveillance (6,7).
The lifetime prevalence of schizophrenia, a serious and chronic psychotic disorder requiring medication, has been estimated at approximately 1% of the U.S. population (8), although the prevalence is higher in lower-income groups, such as the Medicaid population. In fact, Medicaid programs represent the nation’s dominant payers for mental health services (9). In the United States, the treatment of schizophrenia consumes 2.5% of annual adult health care costs, or about $16 to $19 billion (10). The indirect costs of this disorder are far more substantial. Loss of productivity and family burden totaled $46 billion in 1995 (11). Unemployment rates for patients with schizophrenia reach 70% to 80% (12), and it is estimated that patients with schizophrenia constitute 10% of the totally and permanently disabled. Schizophrenia is also associated with an increased incidence of general medical illnesses and increased mortality, especially from suicide. Up to 10% of patients with schizophrenia take their own lives (13).
Since conventional antipsychotics were introduced in the 1950s, antipsychotic drug therapy has been the cornerstone of treatment of persons with schizophrenia. These first-generation antipsychotics are effective in the management of the positive symptoms of psychosis, such as hallucinations and delusions (14). However, their use may cause debilitating side effects, such as extrapyramidal symptoms and tardive dyskinesia (15,16). The pharmacologic profiles of newer, second-generation antipsychotics have a lower risk of extrapyramidal symptoms and are somewhat more effective in the management of negative symptoms of schizophrenia, such as lack of emotion, flattened affect, and low energy (17–19).
Between 1989 and 2002, the U.S. Food and Drug Administration (FDA) approved six second-generation antipsychotics: clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Adverse events associated specifically with second-generation antipsychotics include weight gain and metabolic-syndrome side effects (18,20–22). Adverse events associated with all antipsychotic use include seizures (23–26) and arrhythmias associated with QT prolongation and torsade de pointes (27,28).
Moreover, the risk of these events occurring from the use of antipsychotics may be heightened by concomitant drug therapy and exposure to potentially harmful drug-drug-interactions of medication pairs. Patients with schizophrenia commonly receive multiple medications. Chwastiak and others (29) reported that 53% of patients with schizophrenia who used antipsychotic medication also received drug therapy for a comorbid chronic condition, such as hypertension, diabetes mellitus, coronary artery disease, depression, infections, asthma, congestive heart failure, and chronic obstructive pulmonary disease (COPD) (29).
Potentially harmful drug-drug interactions are often listed on labels for antipsychotic medications. For example, given the potential for QT prolongation, ziprasidone is contraindicated for concomitant use with haloperidol, bupropion, and antiarrhythmics (30,31). Risperidone may interact with a 5-HT6 antagonist, leading to an increase of electroencephalogram alpha and beta bands (32). An interaction between quetiapine and atazanavir or ritonavir may lead to rapid, severe weight gain and increased sedation and mental confusion (33). Substantially reduced serum concentrations of quetiapine occur after lamotrigine exposure (34). Additional evidence of potentially harmful interactions was reported in the recent literature (35–37).
Most antipsychotics are metabolized by the hepatic cytochrome P450 (CYP450) system. CYP450 enzymes CYP1A2, CYP2D6, and CYP3A4 are of particular importance to the metabolism of antipsychotics (38). Concomitant use of an antipsychotic and another drug may competitively inhibit an enzyme that metabolizes the antipsychotic or, alternatively, may induce the action of that enzyme. The result of metabolic inhibition may be a higher plasma level of an antipsychotic, which may result in the adverse events discussed above (38–41). Inducing the enzyme action may result in these or other adverse events, although scant evidence of this possibility has been gathered to date.
Documentation and quantification of exposure of patients with schizophrenia to potentially harmful drug-drug interactions are very limited. This study attempted to identify the proportion of patients with schizophrenia who concomitantly received antipsychotics and other medications that are metabolized by the liver and to estimate the effect of various risk factors on exposure to a potentially harmful interaction. Investigating relationships between such exposures and adverse events was beyond the scope of this study.
Methods
Study design and cohort selection
A retrospective, population-based cohort design was used. The study period was January 2000 to December 2003 (four calendar years). Adult patients aged 18 or older with a diagnosis of schizophrenia who had received at least one prescription for an antipsychotic were selected from a large state's Medicaid claims database. The database includes medical, institutional, and pharmacy claims along with a patient enrollment file. A diagnosis of schizophrenia was indicated by ICD-9 codes 295.xx. Diagnoses were found in either institutional or medical claims. The use of claims databases to identify potentially harmful drug-drug-interaction pairs and adverse events in populations has been well documented (42–46).
A total of 33,567 patients were identified. We excluded 458 patients with ≤90 days of continuous enrollment and 5,200 patients who were aged 65 or older. The final cohort included 27,909 patients. [A figure depicting the selection of study patients is available in an online appendix to this report at ps.psychiatryonline.org.]
To protect patient confidentiality, names, addresses, Medicaid-recipient identification numbers, and other patient identifiers were deleted from the database. A randomized patient number was used as the unique identification. All research data were stored in a stand-alone server with password protection. Only the principal investigator, the data analysis programmer, and the statistician for the project were able to access the patient-level data sets. The research protocol was approved by the University of Cincinnati Medical Center Institutional Review Board.
Drug-drug interaction pairs
Using information from Facts and Comparisons 4.0, we developed systematically a list of clinically significant, potentially harmful pairs of antipsychotics and other medications (47). Because we found in a previous study that second-generation antipsychotics account for a majority of prescriptions for antipsychotics in the Medicaid system (48), we focused on interaction pairs that involved a second-generation drug. However, we considered as well three widely used first-generation antipsychotics: haloperidol, perphenazine, and chlorpromazine (48). Drug-drug interactions can be further categorized by their effects on CYP450 enzymes CYP1A2, CYP2D6, and CYP3A4 and by the type of interaction (enzyme inducers versus enzyme inhibitors) (48).
On the basis of Facts and Comparisons 4.0, potentially harmful interactions are classified into five levels of significance: 1, major; 2, moderate; 3, minor; 4, major or moderate; and 5, minor or any. For the purposes of this study, we examined only major (potentially severe or life threatening) and moderate (less severe but still clinically significant) interactions (significance levels 1, 2, and 4). Focusing on severe and moderate interactions only makes sense given the problem of “alert fatigue” during medication prescribing and dispensing (43,49,50). Some drugs, such as cisapride and troglitazone, were excluded from the study because they were withdrawn from the market prior to the study period. [Potentially harmful interaction pairs investigated are listed in an online appendix to this report.]
Concomitant prescriptions for antipsychotic medications and contraindicated medications were identified from computerized Medicaid pharmacy claims files. All prescriptions (as opposed to only new prescriptions) for these medications were included. Concomitant exposure was defined as an overlap of one or more days in the days of supply of an antipsychotic prescription and a contraindicated medication (47). For example, if a patient had a 20-day prescription for ziprasidone starting on October 29, 2002, and a 30-day prescription for ketoconazole starting on November 18, 2002, one overlap was counted. We decided on the one-day overlap after determining that results and conclusions were not substantially altered with a five- or ten-day overlap requirement. A one-day overlap is consistent with the literature on drug-drug interactions involving hepatic metabolism (43,44). Interaction exposures were further stratified by significance level (severe or moderate), interaction type (inhibitor or inducer), and enzyme type (CYP2D6, CYP1A2, or CYP3A4).
Covariates and confounding factors
The Medicaid recipient eligibility file provided information about the patient’s age, age upon first receiving an antipsychotic medication included in the study, race, and sex. Race was identified as Caucasian, African American, Hispanic, or other. Sex was defined by a dichotomous variable (male=1 and female=0). The file also provided information about other potentially important confounding factors that have gained a lot of interest in recent years (20,51–57). These included alcohol use disorder (ICD-9 code 303.xx), substance use disorders (304.xx), anxiety disorders (300.xx), impulse-control disorders (312.xx), personality disorders (301.xx), and eating disorders (307.5x). Key medical comorbidities included cerebrovascular diseases (433.xx–438.xx), ischemic heart diseases (411.xx–414.xx), neoplasm or cancer (140.xx–208.xx, except 173.xx, 211.5x, 230.xx, 235.xx, and 239.0x), arthritis (711.xx–716.xx), obesity (278.xx), diabetes mellitus (250.xx), hypertension (401.xx), and COPD (496.xx).
Statistical data analysis
All statistical analyses were conducted with SAS for Windows, version 9.1. Descriptive statistics for the study cohort were produced. We calculated the cumulative frequency of clinically significant, potentially harmful interaction pairs among the cohort patients during the study period. Two logistic regression models to determine the potential risk factors associated with exposure to the drug-drug interaction pairs were estimated. The first model included only psychiatric comorbidities, and the second model included psychiatric as well as medical comorbidities.
Results
A total of 6,417 (23%) patients were exposed to potentially harmful interaction pairs (Table 1). (A total of 5,949 and 5,021 patients were exposed if overlaps of five and ten days, respectively, were imposed). The average age of patients who were and were not exposed was 42.5 and 42.2 years, respectively. Compared with patients who were not exposed to potentially harmful interaction pairs, patients who were exposed had significantly higher rates of depression, anxiety disorder, hypertension, obesity, and hyperlipidemia. The proportion of white patients was higher among individuals exposed to potentially harmful interactions than among individuals with no interaction ex-posure.
| Not exposed (N=21,492) | Exposed (N=6,417) | |||
|---|---|---|---|---|
| Characteristic | N | % | N | % |
| Age (M±SD years)b | 42.2±11.2 | 42.5±11.1 | ||
| Femaleb | 10,356 | 48.2 | 3,233 | 50.4 |
| White | 13,792 | 64.2 | 4,635 | 72.2 |
| Age groupb | ||||
| 18–34 | 4,989 | 23.2 | 1,461 | 22.8 |
| 35–49 | 10,523 | 49.0 | 3,089 | 48.1 |
| 50–65 | 5,980 | 27.8 | 1,867 | 29.1 |
| Deceasedb | 649 | 3.0 | 256 | 4.0 |
| Any medication treatment > 12 monthsb | 15,805 | 73.5 | 4,662 | 72.6 |
| Second-generation antipsychotic | ||||
| Clozapine | 20 | .01 | 662 | 10.3 |
| Olanzapine | 24 | .01 | 2,009 | 33.3 |
| Quetiapine | 13 | .01 | 614 | 9.6 |
| Risperidone | 34 | .02 | 2,543 | 39.6 |
| Ziprasidone | 0 | — | 25 | .4 |
| Aripiprazole | 1 | .00 | 39 | .6 |
| Key comorbidityc | ||||
| Psychiatric | ||||
| Depressionb | 2,619 | 12.2 | 971 | 15.1 |
| Substance use disorderb | 5,057 | 23.5 | 1,457 | 22.7 |
| Anxiety disorderb | 2,485 | 11.6 | 866 | 13.5 |
| Impulse-control disorderb | 181 | .8 | 114 | 1.8 |
| Personality disorderb | 1,686 | 7.8 | 566 | 8.8 |
| Eating disorderb | 26 | .12 | 18 | .3 |
| Attention-deficit hyperactivity disorder | 49 | .23 | 17 | .3 |
| Medical | ||||
| Diabetes mellitus | 2,212 | 16.0 | 755 | 11.8 |
| Hypertensionb | 3,446 | 16.0 | 1,134 | 17.7 |
| Chronic obstructive pulmonary disease | 1,168 | 5.4 | 462 | 7.2 |
| Cerebral vascular diseaseb | 243 | 1.1 | 93 | 1.5 |
| Ischemic heart diseaseb | 553 | 2.6 | 184 | 2.9 |
| Arthritisb | 698 | 3.2 | 233 | 3.6 |
| Obesityb | 1,108 | 5.2 | 372 | 5.8 |
| Neoplasmb | 213 | 1.0 | 83 | 1.3 |
| Hyperlipidemiab | 1,163 | 5.4 | 401 | 6.2 |
| Kidney disease | 304 | 1.4 | 101 | 1.6 |
| Liver diseaseb | 204 | 1.0 | 67 | 1.0 |
a
Chi square tests were used to compare patients who were and were not exposed to a potentially dangerous drug-drug interaction for all variables except age and length of treatment, which were compared with Student’s t tests.
b
p<.001, except for p<.05 for comparison of anxiety disorder
c
A patient may have more than one comorbidity.
There were 14,213 interaction exposures among the 6,417 exposed patients (Table 2). The most common pair was the combination of the antipsychotics olanzapine and haloperidol (N=1,353, 9.5%). The next most common combinations were risperidone and sertraline, fluoxetine, paroxetine, and carbamazepine. The combination of quetiapine and ritonavir was not among the top 50 interaction pairs, but ritonavir was prescribed with risperidone or olanzapine. The vast majority of the interactions were of the inhibitor type. The top five interactions involved the enzyme type CYP2D6.
| Frequency | N | % | Antipsychotic | Interacting drug | Significancea | Interaction type | Enzyme type |
|---|---|---|---|---|---|---|---|
| 1 | 1,353 | 9.5 | Olanzapine | Haloperidol | 4 | Inhibitor | 2D6 |
| 2 | 1,217 | 8.6 | Risperidone | Sertraline | 1 | Inhibitor | 2D6 |
| 3 | 1,160 | 8.2 | Risperidone | Fluoxetine | 1 | Inhibitor | 2D6 |
| 4 | 1,046 | 7.4 | Risperidone | Paroxetine | 1 | Inhibitor | 2D6 |
| 5 | 928 | 6.5 | Risperidone E | Carbamazepine | 4 | Inducer | 2D6 |
| 6 | 921 | 6.5 | Olanzapine | Fluoxetine | 4 | Inhibitor | 1A2 |
| 7 | 817 | 5.8 | Clozapine | Sertraline | 1 | Inhibitor | 2D6 |
| 8 | 795 | 5.6 | Olanzapine | Carbamazepine | 4 | Inducer | 1A2 |
| 9 | 674 | 4.7 | Clozapine | Fluoxetine | 1 | Inhibitor | 2D6 |
| 10 | 534 | 3.8 | Clozapine | Citalopram | 1 | Inhibitor | 2D6 |
| 11 | 424 | 3.0 | Risperidone | Ketoconazole | 2 | Inhibitor | 3A4 |
| 12 | 416 | 2.9 | Quetiapine | Carbamazepine | 4 | Inducer | 3A4 |
| 13 | 396 | 2.8 | Haloperidol | Carbamazepine | 2 | Inducer | 3A4 |
| 14 | 311 | 2.2 | Olanzapine | Fluvoxamine | 4 | Inhibitor | 1A2 |
| 15 | 311 | 2.2 | Quetiapine | Phenytoin | 2 | Inducer | 3A4 |
| 16 | 295 | 2.1 | Clozapine | Phenytoin | 4 | Inhibitor | 3A4 |
| 17 | 267 | 1.9 | Olanzapine | Ciprofloxacin | 4 | Inhibitor | 1A2 |
| 18 | 226 | 1.6 | Clozapine | Ciprofloxacin | 4 | Inhibitor | 1A2 |
| 19 | 219 | 1.5 | Risperidone | Thioridazine | 4 | Inhibitor | 2D6 |
| 20 | 179 | 1.3 | Quetiapine | Fluvoxamine | 4 | Inhibitor | 3A4 |
| 21 | 158 | 1.1 | Quetiapine | Ketoconazole | 2 | Inhibitor | 3A4 |
| 22 | 126 | .9 | Quetiapine | Erythromycin | 4 | Inhibitor | 3A4 |
| 23 | 109 | .8 | Clozapine | Fluvoxamine | 1 | Inhibitor | 3A4 |
| 24 | 98 | .7 | Quetiapine | Clarithromycin | 4 | Inhibitor | 3A4 |
| 25 | 83 | .6 | Haloperidol | Ketoconazole | 2 | Inhibitor | 3A4 |
| 26 | 70 | .5 | Perphenazine | Paroxetine | 2 | Inhibitor | 2D6 |
| 27 | 69 | .5 | Clozapine | Carbamazepine | 4 | Inducer | 3A4 |
| 28 | 67 | .5 | Risperidone | Fluconazole | 2 | Inhibitor | 3A4 |
| 29 | 67 | .5 | Chlorpromazine | Trazodone | 4 | Inhibitor | 2D6 |
| 30 | 57 | .4 | Olanzapine | Clomipramine | 4 | Inhibitor | 2D6 |
| 31 | 56 | .4 | Quetiapine | Fluconazole | 2 | Inhibitor | 3A4 |
| 32 | 50 | .4 | Olanzapine | Ritonavir | 2 | Inhibitor | 1A2 |
| 33 | 49 | .4 | Perphenazine | Phenytoin | 4 | Inducer | 3A4 |
| 34 | 48 | .4 | Haloperidol | Fluphenazine | 4 | Inhibitor | 2D6 |
| 35 | 47 | .3 | Chlorpromazine | Phenytoin | 4 | Inhibitor | 3A4 |
| 36 | 42 | .3 | Aripiprazole | Fluoxetine | 4 | Inhibitor | 2D6 |
| 37 | 38 | .3 | Chlorpromazine | Fluoxetine | 1 | Inhibitor | 2D6 |
| 38 | 36 | .3 | Chlorpromazine | Haloperidol | 4 | Inhibitor | 2D6 |
| 39 | 35 | .3 | Risperidone | Itraconazole | 2 | Inhibitor | 3A4 |
| 40 | 34 | .2 | Aripiprazole | Carbamazepine | 2 | Inducer | 3A4 |
| 41 | 34 | .2 | Haloperidol | Thioridazine | 4 | Inhibitor | 2D6 |
| 42 | 34 | .2 | Haloperidol | Fluvoxamine | 4 | Inhibitor | 1A2 |
| 43 | 31 | .2 | Chlorpromazine | Paroxetine | 2 | Inhibitor | 2D6 |
| 44 | 29 | .2 | Risperidone | Nelfinavir | 4 | Inhibitor | 3A4 |
| 45 | 28 | .2 | Clozapine | Cimetidine | 4 | Inhibitor | 1A2 |
| 46 | 22 | .2 | Ziprasidone | Carbamazepine | 2 | Inducer | 3A4 |
| 47 | 21 | .2 | Chlorpromazine | Propranolol | 1 | Inhibitor | 1A2 |
| 48 | 19 | .1 | Risperidone | Ritonavir | 4 | Inhibitor | 3A4 |
| 49 | 17 | .1 | Clozapine | Phenobarbital | 2 | Inducer | 3A4 |
| 50 | 16 | .1 | Perphenazine | Haloperidol | 4 | Inhibitor | 2D6 |
| Other | 134 | .9 |
a
Potentially harmful drug-drug interactions are classified by Facts and Comparisons 4.0 (47) into five levels of significance: 1, major; 2, moderate; 3, minor, 4, major or moderate; and 5, minor or any; interactions classified as level 1, 2, or 4 are the subject of this study.
Most patients who were exposed to potentially harmful drug-drug interactions were not exposed through multiple physicians and pharmacies. In fact, 4,725 patients had at least one exposure from the same pharmacy, and 4,032 patients were exposed by the same physician (Table 3). Same-day exposures were not uncommon. Again, 2,645 patients were exposed by the same pharmacy on the same day, and 2,447 patients were exposed by the same prescriber on the same day.
| Any exposure | Same-day exposure | |||
|---|---|---|---|---|
| Variable | N | % | N | % |
| Same prescriber | 4,032 | 14.4 | 2,447 | 8.8 |
| Same pharmacy | 4,725 | 16.9 | 2,645 | 9.5 |
Table 4 shows patients exposed to interactions stratified by the antipsychotic taken, the significance of the interaction, the interaction type (inhibitor or inducer), and the enzyme type. Patients taking risperidone were the most likely to be exposed to an interaction—13.1% of the cohort was exposed to a potentially harmful medication pair involving risperidone. The next most common combinations involved olanzapine (10.3% of patients), quetiapine (3.3%), and clozapine (3.2%). The percentage of patients exposed to interaction pairs was highest for category 4 (major or moderate) interactions and lowest for category 2 (moderate) interactions. The percentage of patients exposed to enzyme type CYP2D6 (14.7%) was higher than the percentage exposed to either CYP3A4 (5.4%) or CYP1A2 (5.2%).
| Any exposure | Same-day exposure | |||
|---|---|---|---|---|
| Variable | N | % | N | % |
| Significanceb | ||||
| 1 | 2,582 | 9.3 | 1,566 | 5.6 |
| 2 | 963 | 3.5 | 251 | .9 |
| 4 | 3,505 | 12.6 | 1,715 | 6.2 |
| Enzyme for metabolism | ||||
| 1A2 | 1,465 | 5.2 | 742 | 2.7 |
| 2D6 | 4,108 | 14.7 | 2,369 | 8.5 |
| 3A4 | 1,496 | 5.4 | 411 | 1.5 |
| Antipsychotic | ||||
| Aripiprazole | 76 | .3 | 32 | .1 |
| Clozapine | 899 | 3.2 | 262 | .9 |
| Olanzapine | 2,882 | 10.3 | 1,453 | 5.2 |
| Quetiapine | 931 | 3.3 | 273 | 1.0 |
| Risperidone | 3,651 | 13.1 | 2,074 | 7.4 |
| Ziprasidone | 32 | .1 | 13 | .1 |
| Chlorpromazine | 211 | .8 | 94 | .3 |
| Haloperidol | 430 | 1.5 | 135 | .5 |
| Perphenazine | 119 | .4 | 50 | .2 |
a
Patients may be exposed to more than one potentially dangerous drug-drug interaction.
b
Potentially harmful drug-drug interactions are classified by Facts and Comparisons 4.0 (47) into five levels of significance: 1, major; 2, moderate; 3, minor; 4, major or moderate; and 5, minor or any; interactions classified as level 1, 2, or 4 are the subject of this study.
The results of a logistic regression that predicted exposure to a potentially harmful interaction pair are shown in Table 5. A higher risk of exposure was associated with being female (odds ratio [OR]=.94), being white (OR=1.43), having depression (OR=1.21), having impulse-control disorder (OR=1.99), or having an eating disorder (OR=2.16). COPD was the only medical comorbidity estimated to have a statistically significant effect on exposure (OR=1.20).
| Model 1 | Model 2 | |||
|---|---|---|---|---|
| Characteristic | OR | 95% CI | OR | 95% CI |
| Sex (reference: female) | .929 | .877–.984 | .935 | .882–.991 |
| Race (reference: other) | 1.425 | 1.339–1.517 | 1.430 | 1.343–1.523 |
| Age | 1.001 | .999–1.004 | .999 | .997–1.002 |
| Deceased (reference: not deceased) | 1.295 | 1.114–1.505 | 1.246 | 1.069–1.453 |
| Any medication treatment >12 months (reference: <12 months) | .965 | .905–1.030 | .946 | .886–1.010 |
| Key comorbidity (reference: not present) | ||||
| Psychiatric | ||||
| Depression | 1.236 | 1.134–1.346 | 1.206 | 1.106–1.315 |
| Substance use disorder | .958 | .892–1.029 | .936 | .870–1.006 |
| Anxiety disorder | 1.096 | 1.002–1.200 | 1.076 | .983–1.178 |
| Impulse-control disorder | 2.014 | 1.586–2.557 | 1.986 | 1.564–2.522 |
| Personality disorder | 1.013 | .911–1.126 | .994 | .893–1.105 |
| Eating disorder | 2.089 | 1.139–3.834 | 2.158 | 1.176–3.958 |
| Attention-deficit hyperactivity disorder | 1.087 | .624–1.894 | 1.091 | .626–1.901 |
| General medical | ||||
| Diabetes mellitus | — | — | 1.095 | .996–1.204 |
| Hypertension | — | — | 1.083 | .996–1.177 |
| Chronic obstructive pulmonary disease | — | — | 1.201 | 1.066–1.353 |
| Cerebrovascular disease | — | — | 1.138 | .889–1.456 |
| Ischemic heart disease | — | — | .953 | .798–1.138 |
| Arthritis | — | — | 1.011 | .865–1.182 |
| Obesity | — | — | 1.035 | .912–1.176 |
| Cancer or tumor | — | — | 1.120 | .862–1.456 |
| Hyperlipidemia | — | — | 1.062 | .940–1.200 |
| Kidney disease | — | — | 1.073 | .851–1.352 |
| Liver disease | — | — | 1.076 | .813–1.425 |
a
Goodness of fit for both models was significant (χ2=245.37, −2 log likelihood=29,851, p<.001, model 1, and χ2=273.45, −2 log likelihood=29,823, p<.001, model 2).
Discussion
This study was a longitudinal, retrospective analysis of a large state's Medicaid claims database that quantified the proportion of patients with schizophrenia exposed to potentially harmful drug-drug interactions involving antipsychotic medication. Nearly one-quarter of patients (N=6,417) with schizophrenia were exposed to clinically significant interaction pairs with a risk of adverse events such as seizures or QT prolongation. A majority of patients who were exposed to a potentially harmful drug-drug interaction were prescribed the drugs by the same physician (N=4,032) or the same pharmacy (N=4,725). This finding is consistent with the findings of a similar study conducted by Howe and colleagues (58) with a PHARMetrics database. Frois and others (59) reported that only 9.2% of psychiatrists considered themselves well-informed about antipsychotic drug-drug interactions, and only 19.8% tracked antipsychotic-related drug-drug interactions in their practices.
Interestingly, the results of this study were similar to those of a study by Jones and others (43) of cisapride and contraindicated medications metabolized by enzyme type CPY3A4. Of all the potentially harmful interaction pairs, 50% were found to be prescribed by the same physician for the same patient, 89% were dispensed by the same pharmacy for the same patient, and 17% were dispensed on the same day for the same patient (43,44).
Our study suggests that both prescribing and pharmacy-based dispensing may represent important intervention points for preventing potentially harmful interactions. Moreover, much intervention may be accomplished without involving complicated communications among different physicians or pharmacies. The results from this study indicate that certain comorbidities, such as depression and COPD, are associated with a higher risk of a potentially harmful interaction. Prescribers need to be aware of these higher risks and monitor their prescribing habits for patients suffering from multiple diseases.
The literature suggests that although most pharmacies have computer-based warning systems, these systems do not consistently prevent the dispensing of contraindicated drugs. Possible reasons for such inconsistent prevention include pharmacy-based drug information systems that embed contraindications in a large volume of other material, making them difficult to find; warning systems that do not present current information in a rationally prioritized layout; and pharmacists’ concerns about questioning the prescribing physicians’ decisions (21,43).
Regardless of potentially harmful drug-drug interactions, choosing a specific antipsychotic is nontrivial. Recent studies have associated metabolic effects, such as weight gain, diabetes mellitus, and dyslipidemia, with some of the second-generation antipsychotics, such as olanzapine and risperidone (46,60). First-generation antipsychotic drugs carry high risks of parkinsonism and tardive dyskinesia (48). Risks and benefits of the various pharmacologic treatments available must be carefully analyzed.
Jing and colleagues (48) reported that utilization of antipsychotic medication in state Medicaid programs increased dramatically in recent years because second-generation antipsychotic agents are now used to manage conditions other than schizophrenia. These drugs, except for clozapine, have been approved for use by the U.S. Food and Drug Administration (FDA) for bipolar disorder and are often prescribed for that condition. They are also often prescribed, off label, for obsessive-compulsive disorder, borderline personality disorder, and autism. A black box warning by the FDA in 2005 slowed their use by elderly patients for treatment of behavioral and psychological symptoms of dementia (61). Identification and quantification of potentially harmful drug-drug interactions are clearly important for these additional populations and will require further study.
Of course, finding that patients with comorbidities are at a greater risk of potentially harmful drug-drug interactions is not particularly surprising. After all, taking more prescription medications automatically puts patients at greater risk. However, not all comorbidities were associated with a higher risk, so this explanation is not generally satisfying. White patients and female patients experienced a significantly higher risk of a potentially harmful interaction. The use of antidepressants to treat major depressive disorder, impulse-control disorder, and eating disorders and the relationship between the incidence of these comorbidities with gender and race may involve a complicated interaction that increases the risk among a certain group of patients. In fact, estimates of a statistically significant association between death and potentially harmful interactions do not indicate the direction of causation. Although it is possible that the interaction led to the patient’s death, it is also possible, given our study design, that sicker patients were both more likely to die as well as to experience a drug-drug interaction (Table 5).
The results of this study may not be generalizable to other managed-care populations or to other diseases because the study population was limited to a state's Medicaid patients with schizophrenia. The design of the study limits the ability to infer the impact of potentially harmful drug pairs on resource use and cost. Further research with a prospective design is needed to explore these relationships. There were limited clinical data to validate exposure to potentially harmful interactions.
Because this study was based on claims from pharmacies and medical offices, we were unable to determine how often physicians chose to avoid or pharmacists chose not to dispense contraindicated medication pairs or how often pharmacists called physicians to question the prescriptions. We also could not determine how often pharmacists dispensed overlapping prescriptions for an antipsychotic and a contraindicated medication but instructed the patient to discontinue one of the medications while taking the other.
Moreover, regardless of whether physicians are well aware of the literature on potentially harmful effects of combining some drugs, the perceived benefit of the treatment regimen may outweigh the risks, especially for some patients with severe mental illness. The physicians may be cautious and carefully monitor patient response in order to minimize the risk of an adverse event. Unfortunately, this type of detail cannot be captured by a study of such a large database.
Conclusions
One-fourth of patients with schizophrenia were exposed to potentially harmful drug-drug interactions. Because many of these patients were exposed by the same prescriber or the same pharmacy, and even on the same day, simple interventions by both physicians and pharmacies are recommended. Practitioners should be aware of the possible clinical consequences stemming from certain pairs of antipsychotics and other drugs. Meanwhile, pharmacies need good systems in place to catch prescriptions for two contraindicated medications.
Acknowledgments and disclosures
This project received educational grant support from Ortho-McNeil Janssen Scientific Affairs, L.L.C. The authors thank William H. Olson, C.V. Damaraju, Steve Ascher, Riad Dirani, Jessica M. Panish, and George Wong for their invaluable suggestions and support regarding research design and data analysis techniques, and they appreciate the comments of colleagues at the University of Cincinnati Medical Center.
Dr. Wu was employed by Johnson & Johnson at the time of this research . Dr. Jing, a graduate student at the time of this research, is an employee of Bristol-Myers Squibb and owns stock in the company. Dr. Keck is a paid consultant to the advisory board of Bristol-Myers Squibb and to Pamlab and is a coinventor (U.S. patent 6,387,956) of a method of tramadol administration for treatment of obsessive-compulsive spectrum disorder. He has received no financial gain from this patent. Dr. Patel receives grant support or is under contract to AstraZeneca, Janssen Scientific Affairs, and Pfizer, Inc. The other authors report no competing interests.
Supplementary Material
Supplemental Material (1080_ds001.pdf)
- Download
- 91.61 KB
References
1.
Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmaceutical Association 41:192–199, 2001
2.
Johnson JA, Bootman JL: Drug-related morbidity and mortality: a cost-of-illness model. Archives of Internal Medicine 155:1949–1956, 1995
3.
Kohn LT, Corrigan JM, Donaldson MS (eds): To Err Is Human: Building a Safer Health System. Washington, DC, National Academy Press, 1999
4.
Chrischilles EA, Segar ET, Wallace RB: Self-reported adverse drug reactions and related resource use: a study of community-dwelling persons 65 years of age and older. Annals of Internal Medicine 117:634–640, 1992
5.
Hanlon JT, Weinberger M, Samsa GP, et al.: A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. American Journal of Medicine 100:428–437, 1996
6.
Kelly WN: Potential risks and prevention, part 2: drug-induced permanent disabilities. American Journal of Health-System Pharmacy 58:1325–1329, 2001
7.
Marcellino K, Kelly WN: Potential risks and prevention, part 3: Drug-induced threats to life. American Journal of Health-System Pharmacy 58:1399–1405, 2001
8.
McCombs JS, Nichol MB, Stimmel GL, et al.: Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. Journal of Clinical Psychiatry 60(suppl 19):5–11, 1999
9.
Koyanagi C, Forquer S, Alfano E: Medicaid policies to contain psychiatric drug costs. Health Affairs (Project Hope) 24:536–544, 2005
10.
Rupp A, Keith SJ: The cost of schizophrenia: assessing the burden. Psychiatric Clinics of North America 16:413–423, 1993
11.
Wyatt RJ, Henter I, Leary MC, et al.: An economic evaluation of schizophrenia–1991. Social Psychiatry and Psychiatric Epidemiology 30:196–205, 1995
12.
Attkisson C, Cook J, Karno M, et al.: Clinical services research. Schizophrenia Bulletin 18:561–626, 1992
13.
Tsuang MT: Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 35:153–155, 1978
14.
Stroup AL, Manderscheid RW: The development of the state mental hospital system in the United States. Journal of the Washington Academy of Sciences 78:59–68, 1988
15.
Lyu RR, McCombs JS, Johnstone BM, et al.: Use of conventional antipsychotics and the cost of treating schizophrenia. Health Care Financing Review 23:83–99, 2001
16.
Worrel JA, Marken PA, Beckman SE, et al.: Atypical antipsychotic agents: a critical review. American Journal of Health-System Pharmacy 57:238–255, 2000
17.
Kane J, Honigfeld G, Singer J, et al.: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789–796, 1988
18.
Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209–1223, 2005
19.
Nasrallah HA: Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Annals of Clinical Psychiatry 18:57–62, 2006
20.
Guo JJ, Keck PE, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry 67:1055–1061, 2006
21.
Koro CE, Fedder DO, L’Italien GJ, et al.: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. British Medical Journal 325:243–248, 2002
22.
Keck PE, Marcus R, Tourkodimitris S, et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160:1651–1658, 2003
23.
Bonelli RM: Olanzapine-associated seizure. Annals of Pharmacotherapy 37:149–150, 2003
24.
Dogu O, Sevim S, Kaleagasi HS: Seizures associated with quetiapine treatment. Annals of Pharmacotherapy 37:1224–1227, 2003
25.
Balit CR, Isbister GK, Hackett LP, et al.: Quetiapine poisoning: a case series. Annals of Emergency Medicine 42:751–758, 2003
26.
Malik AR, Ravasia S: Aripiprazole-induced seizure. Canadian Journal of Psychiatry 50:186, 2005
27.
Liperoti R, Gambassi G, Lapane KL, et al.: Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine 165:696–701, 2005
28.
Rettenbacher MA, Eder-Ischia U, Bader A, et al.: QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. Journal of Clinical Psychopharmacology 25:206–210, 2005
29.
Chwastiak L, Rosenheck R, Leslie D: Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample. Medical Care 44:55–61, 2006
30.
Miceli JJ, Tensfeldt TG, Shiovitz T, et al.: Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clinical Therapeutics 32:472–491, 2010
31.
Biswas AK, Zabrocki LA, Mayes KL, et al.: Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. Journal of Toxicology and Clinical Toxicology 41:101–104, 2003
32.
Liem-Moolenaar M, Rad M, Zamuner S, et al.: Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. British Journal of Clinical Pharmacology 71:907–916, 2011
33.
Pollack TM, McCoy C, Stead W: Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 29:1386–1391, 2009
34.
Andersson ML, Björkhem-Bergman L, Lindh JD: Possible drug-drug interaction between quetiapine and lamotrigine—evidence from a Swedish TDM database. British Journal of Clinical Pharmacology 72:153–156, 2011
35.
Kumar D, Muppa M, Kablinger A: A cytochrome P450 inhibitor in a stable schizophrenic patient: a drug interaction. Journal of Clinical Psychopharmacology 31:670–671, 2011
36.
De Dios C, Fudio S, Lorenzo A: Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. Journal of Clinical Pharmacy and Therapeutics 36:430–432, 2011
37.
Huang CC, Wei IH: Unexpected interaction between quetiapine and valproate in patients with bipolar disorder. General Hospital Psychiatry 32:446e1–446e2, 2010
38.
Sandson NB, Armstrong SC, Cozza KL: Med-psych drug-drug interactions update: an overview of psychotropic drug-drug interactions. Psychosomatics 46: 464–494, 2005
39.
Davies SJC, Eayrs S, Pratt P, et al.: Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. British Journal of Clinical Pharmacology 57:464–472, 2004
40.
Chadwick B, Waller DG, Edwards JG: Potentially hazardous drug interactions with psychotropics. Advances in Psychiatric Treatment 11:440–449, 2005
41.
Sharif ZA: Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Journal of Clinical Psychiatry 5(suppl 6):22–25, 2003
42.
Miwa LJ, Jones JK, Pathiyal A, et al.: Value of epidemiologic studies in determining the true incidence of adverse events: the nonsteroidal anti-inflammatory drug story. Archives of Internal Medicine 157:2129–2136, 1997
43.
Jones JK, Fife D, Curkendall S, et al.: Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286:1607–1609, 2001
44.
Guo JJ, Curkendall S, Jones JK, et al.: Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiology and Drug Safety 12:295–301, 2003
45.
Guo JJ, Jang R, Louder A, et al.: Acute pancreatitis associated with different drug therapies among patients infected with human immunodeficiency virus. Pharmacotherapy 25:1044–1054, 2005
46.
Guo JJ, Keck PE, Li H, et al.: Bipolar-related and comorbidity treatment costs for patients with bipolar disorder in Medicaid. Psychiatric Services 58:1073–1078, 2007
47.
Facts and Comparisons 4.0: Drug Interaction Facts. St. Louis, Mo, Wolters Kluwer, 2006
48.
Jing Y, Kelton CML, Guo JJ, et al.: Price, utilization, and spending for antipsychotic medications in the Medicaid program. Drug Benefit Trends 19:27–41, 2007
49.
Malone DC, Abarca J, Hansten PD, et al.: Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. Journal of the American Pharmaceutical Association 44:142–151, 2004
50.
Malone DC, Hutchins DS, Haupert H, et al.: Assessment of potential drug-drug interactions with a prescription claims database. American Journal of Health-System Pharmacy 62:1983–1991, 2005
51.
Keck PE, Buffenstein A, Ferguson J, et al.: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trail. Psychopharmacology 140:173–184, 1998
52.
Lora A, Conti V, Leoni O, et al.: Adequacy of treatment for patients with schizophrenia spectrum disorders and affective disorders in Lombardy, Italy. Psychiatric Services (Washington, D.C.) 62:1079–1084, 2011
53.
Aschbrenner KA, Cai S, Grabowski DC, et al.: Medical comorbidity and functional status among adults with major mental illness newly admitted to nursing homes. Psychiatric Services (Washington, D.C.) 62:1098–1100, 2011
54.
Lan CC, Su TP, Chen YS, et al: Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson’s disease. General Hospital Psychiatry 33:411e3–411e5, 2011
55.
Hus JH, Chien IC, Lin CH, et al.: Incidence of diabetes in patients with schizophrenia: a population-based study. Canadian Journal of Psychiatry 56:19–26, 2011
56.
Felmet K, Zisook S, Kasckow JW: Elderly patients with schizophrenia and depression: diagnosis and treatment. Clinical Schizophrenia and Related Psychoses 4:239–250, 2011
57.
Guo JJ, Keck PE, Li H, et al.: Diabetes associated with antipsychotic use among Medicaid patients with bipolar disorders: a nested case-control study. Pharmacotherapy 27:27–35, 2007
58.
Howe AM, Kozma C, Russo P, et al: The prevalence of potential antipsychotic drug-drug interactions in a large US national managed care database. Presented at the Annual US Psychiatric and Mental Health Congress, New Orleans, La, Nov 15–19, 2006
59.
Frois C, Guerin A, Saraogi A, et al.: Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics. Current Medical Research and Opinion 26:2735–2744, 2010
60.
Cavuto NJ, Woosley RL, Sale M: Pharmacies and prevention of potentially fatal drug interactions. JAMA 275:1086–1087, 1996
61.
Dorsey ER, Rabbani A, Gallagher SA, et al.: Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170:96–103, 2010
Information & Authors
Information
Published In
Cover: Untitled, by Robert Rauschenberg, 1963. Oil, silkscreened ink, metal, and plastic on canvas; 82 × 48 × 6¼ inches. Solomon R. Guggenheim Museum, New York, purchased with funds contributed by Elaine and Werner Dannheisser and the Dannheisser Foundation (82.2912).
History
Published online: 1 November 2012
Published in print: November 2012
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).